DGX financials
Quest Diagnostics Incorporated · end-of-day data as of Oct 16, 2026
Quest Diagnostics Incorporated
$235.00+3.5%
Buy · 18 analystsPT $233.86 -0.5%
DGX reported revenue of $3.04B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 10.2% from a year earlier. It posted diluted EPS of $2.84, free cash flow of $330M and a net margin of 10.5%.
Valuation
- P/E24.9x
- P/E vs own+15.6%
- P/E vs sector-11.4%
- FCF yield+4.7%
- Market cap$25.94B
Quarterly results
Q2 FY2026: Revenue +10.2% year over year, free cash flow 10.8% of revenue, operating margin 15.1%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $3.04B | 2.84 | $330M | 33.7% | 15.1% | 10.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.9B | 2.24 | $164M | 32.5% | 13.8% | 8.7% |
| Q4 FY2025 | Dec 31, 2025 | $2.81B | 2.18 | $307M | 32.6% | 13.9% | 8.7% |
| Q3 FY2025 | Sep 30, 2025 | $2.82B | 2.16 | $419M | 33.7% | 13.7% | 8.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.76B | 2.47 | $436M | 34.2% | 15.9% | 10.2% |
| Q1 FY2025 | Mar 31, 2025 | $2.65B | 1.94 | $197M | 32.5% | 13.0% | 8.3% |
| Q4 FY2024 | Dec 31, 2024 | $2.62B | 1.95 | $341M | 32.7% | 13.8% | 8.5% |
| Q3 FY2024 | Sep 30, 2024 | $2.49B | 1.99 | $250M | 32.6% | 13.3% | 9.1% |
| Q2 FY2024 | Jun 30, 2024 | $2.4B | 2.04 | $268M | 33.5% | 14.8% | 9.6% |
| Q1 FY2024 | Mar 31, 2024 | $2.37B | 1.72 | $50M | 32.6% | 12.7% | 8.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.29B | 1.70 | $455M | 32.3% | 11.7% | 8.4% |
| Q3 FY2023 | Sep 30, 2023 | $2.29B | 1.96 | $102M | 32.9% | 14.9% | 9.8% |